)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Vistin Pharma
Vistin Pharma (VISTN) investor relations material
Vistin Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 revenue was NOK 108.4m, broadly unchanged YoY, while EBITDA was NOK 18.852m vs NOK 28.047m; record sales volume rose 13% to 1,610 MT.
Jan–Sep sales volume increased 10% to 4,710 MT, while revenue declined 6% to NOK 320.808m and EBITDA to NOK 68.234m; currency-neutral revenue was approximately flat.
A four-week Q4 maintenance stop to replace the main distillation vessel will idle both production lines and constrain quarterly production and sales.
Financial highlights
Q3 revenue was NOK 108.4m vs NOK 108.8m YoY; FX-neutral revenue increased ~7%, offset by lower average selling prices and stronger NOK.
Q3 EBITDA was NOK 18.852m vs NOK 28.047m; EBIT was NOK 12.972m vs NOK 21.344m, and net profit was NOK 10.946m vs NOK 18.525m.
Jan–Sep revenue was NOK 320.808m vs NOK 341.546m; EBITDA was NOK 68.234m vs NOK 88.536m, and net profit was NOK 46.574m vs NOK 58.694m.
Q3 operating expenses were NOK 89.5m vs NOK 80.8m, mainly reflecting higher volume and raw-material costs; salary costs benefited from no bonus accrual vs NOK 2.5m in Q3 2025.
Q3 net finance was positive NOK 0.1m vs NOK 2.4m; Jan–Sep net finance was positive NOK 8.2m vs NOK 3.7m.
Outlook and guidance
Q4 gross-margin recovery is expected as most higher-priced raw materials purchased during the Hormuz disruption have been consumed.
2027 sales volume is expected to increase from Q3 levels; management expects process fine-tuning to support the 7,000 MT target without significant CapEx.
Existing capacity is up to ~7,000 MT annually; further capacity and unit-cost improvements are under review.
Metformin demand is forecast to grow 4%–6% annually; growth, productivity and sustainability require additional CapEx, while volume growth and safety-stock plans may raise working-capital needs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vistin Pharma
- Q2 2026 saw lower revenue and EBITDA but higher sales volume and strong margins, with a NOK 1 dividend paid.VISTN
Q2 2026 - Rising diabetes prevalence fuels metformin demand, supporting growth and shareholder returns.VISTNRedeye Theme Event Diabetes presentation
- Q1 2026 delivered strong sales volume, stable profit, and a dividend proposal amid supply risks.VISTNQ1 2026
- Rising global diabetes drives metformin demand, supporting growth, dividends, and expansion plans.VISTNDNB Carnegie Nordic SMB Conference presentation
- Record 2025 revenue, sales, and profit growth, with strong margins and a higher dividend proposed.VISTNQ4 2025
- Record EBITDA and production volume achieved amid lower revenue and strong cost control.VISTNQ3 2024
- Record EBITDA and net profit growth in Q2 2024, with strong margins and strategic expansion.VISTNQ2 2024
- Double-digit revenue and profit growth, high margins, and a proposed NOK 1.25 dividend.VISTNQ1 2025
- Record EBITDA, strong margins, and higher dividends highlight robust 2024 growth outlook.VISTNQ4 2024
Next Vistin Pharma earnings date
Q4 202612 Feb, 2027
Vistin Pharma
Next Vistin Pharma earnings date
Q4 202612 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Vistin Pharma AS is a global pharmaceutical company that produces and markets active pharmaceutical ingredients. The company offers its products to an extensive network of third party manufacturers. In addition, the company develops its own formulations that are produced and marketed by the Vistin Pharma AS subsidiary. As well as producing bulk APIs, Vistin Pharma has a wide range of products in different stages of development that it expects will be launched in 2016.
Vistin Pharma has experienced continued growth in demand for its products, both due to the expansion of the pharma industry and from the increasing amount of specialised niche pharmaceuticals being developed. Its focus is on supplying products for diabetes and autoimmunity therapies as well as antibiotics. The company was incorporated in 2015 and is headquartered in Oslo, Norway.